IP Library Granted Patent US 10,407,434
Granted Patent B2
US 10,407,434 · App. 16/262,683 · Granted Sep 10, 2019

Process for preparing oxycodone compositions

Inventors: Robert Chapman (Downingtown, PA); Lonn S. Rider (Foster, RI); Qi Hong (Sharon, MA); Donald Kyle (Yardley, PA); Robert Kupper (East Greenwich, RI)
Assignees: PURDUE PHARMA L.P.; THE P.F. LABORATORIES, INC.; PURDUE PHARMACEUTICALS L.P.; RHODES TECHNOLOGIES
C07D489/08A61K9/14A61K9/20A61K9/2095A61K9/48A61K9/4833A61K31/485C07D489/02C07D489/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,407,434
App. No.
16/262,683
Granted
Sep 10, 2019
Kind
B2
Abstract

In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.

Claims (24)

1. A process of purifying oxycodone free base or oxycodone HCl that contains 8α,14-dihydroxy-7,8-dihydrocodeinone or HCl salt thereof, said process comprising:

(i) reducing the amount of 8α,14-dihydroxy-7,8-dihydrocodeinone or HCl salt thereof in the oxycodone free base or oxycodone HCl;

(ii) dissolving the resultant oxycodone free base or oxycodone HCl from step (i) in a suitable recrystallization solvent;

(iii) cooling the recrystallization solvent to precipitate purified oxycodone free base or oxycodone HCl; and

(iv) recovering the purified oxycodone free base or oxycodone HCl.

2. The process of claim 1 , wherein the ratio of 8α,14-dihydroxy-7,8-dihydrocodeinone or HCl salt thereof to oxycodone free base or oxycodone HCl following step (i) is 0.04% or less as measured by HPLC.

3. The process of claim 1 , wherein at least 1 kg of the oxycodone free base or oxycodone HCl is purified.

4. The process of claim 1 , wherein step (i) is carried out by hydrogenation.

5. The process of claim 4 , wherein the hydrogenation is carried out one or more times at a temperature between 40° C. and 85° C.

6. The process of claim 5 , wherein the hydrogenation step reduces the amount of 14-hydroxycodeinone in the oxycodone free base or oxycodone HCl.

7. The process of claim 6 , wherein less than 10 ppm of 14-hydroxycodeinone is present following step (iv).

8. The process of claim 6 , wherein no 14-hydroxycodeinone are present following step (iii).

9. The process of claim 4 , wherein step (i) is carried out in a solvent suitable for hydrogenation.

10. The process of claim 9 , wherein the hydrogenation reaction is carried out at a pH lower than 1.0.

11. The process of claim 10 , further comprising raising the pH of the reaction following step (i) or step (ii).

12. The process of claim 1 , wherein the hydrogenation is carried out for a time between 4 hours and 36 hours.

13. The process of claim 1 , wherein the starting oxycodone free base or oxycodone HCl was formed by hydrogenation of 14-hydoxycodienone.

14. The process of claim 2 , wherein the starting oxycodone free base or oxycodone HCl was formed by hydrogenation of 14-hydoxycodienone.

15. The process of claim 1 , wherein the process comprises purifying oxycodone free base.

16. The process of claim 1 , wherein the process comprises purifying oxycodone HCl.

17. The process of claim 2 , wherein the process comprises purifying oxycodone free base.

18. The process of claim 2 , wherein the process comprises purifying oxycodone HCl.

19. Purified oxycodone free base prepared according to the process of claim 2 , wherein the ratio of 8 α, 14-dihydroxy-7,8-dihydrocodeinone to oxycodone free base is 0.04% or less as measured by HPLC.

20. Purified oxycodone HCl prepared according to the process of claim 2 , wherein the ratio of 8 α, 14-dihydroxy-7,8-dihydrocodeinone HCl salt to oxycodone HCl is 0.04% or less as measured by HPLC.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 19, 2019
From: THE P.F. LABORATORIES, INC.; PURDUE PHARMA TECHNOLOGIES, INC.
To: PURDUE PHARMA L.P.
Reel/Frame 048936/0093 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2019
From: CHAPMAN, ROBERT S.; RIDER, LONN S.; HONG, QI; KYLE, DONALD; KUPPER, ROBERT
To: EURO-CELTIQUE S.A.
Reel/Frame 048195/0165 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2019
From: EURO-CELTIQUE S.A.
To: PURDUE PHARMA L.P.
Reel/Frame 048195/0333 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2019
From: PURDUE PHARMA L.P.
To: PURDUE PHARMA L.P.; THE P.F. LABORATORIES, INC.; PURDUE PHARMACEUTICALS L.P.; RHODES TECHNOLOGIES
Reel/Frame 048195/0619 →
Continuity (15)
Continuation 15721167 · Sep 29, 2017
Continuation 15058420 · Mar 2, 2016
Continuation 14725210 · May 29, 2015
Continuation 13366755 · Feb 6, 2012
Continuation 12893681 · Sep 29, 2010
Continuation 12380800 · Mar 4, 2009
Continuation 11653529 · Jan 16, 2007
Continuation 11391897 · Mar 29, 2006
Continuation 11093626 · Mar 30, 2005
Provisional Application 60651778 · Feb 10, 2005
Provisional Application 60648625 · Jan 31, 2005
Provisional Application 60620072 · Oct 18, 2004
Provisional Application 60601534 · Aug 13, 2004
Provisional Application 60557492 · Mar 30, 2004
Related Publication 20190161492A1 · May 30, 2019